Tıbbi Farmakoloji Anabilim Dalı, Tıp Fakültesi, Çukurova Üniversitesi, Sarıçam, Adana, Turkey.
Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
Adv Ther. 2020 Jun;37(6):2575-2579. doi: 10.1007/s12325-020-01351-9. Epub 2020 Apr 29.
The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a "Public Health Emergency of International Concern" (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials. According to the CDC and Chinese treatment guidelines for COVID-19, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19. Until now, it is still unclear which drug can successfully fight against the disease. Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level.
世界卫生组织（WHO）将冠状病毒传染病-2019（COVID-19）的爆发称为“国际关注的突发公共卫生事件”（PHEIC）。根据世界卫生组织、美国疾病控制与预防中心（CDC）和美国食品和药物管理局（FDA）的说法，目前尚无被声称可用于预防或治疗 COVID-19 的药物或疫苗。一些现有的抗病毒药物，以前是为治疗严重急性呼吸系统综合症（SARS）、中东呼吸系统综合症（MERS）、人类免疫缺陷病毒（HIV）和疟疾而开发或使用的，正在被研究用于 COVID-19 的治疗，其中一些正在进行临床试验。根据 CDC 和中国 COVID-19 的治疗指南，氯喹、羟氯喹、洛匹那韦/利托那韦和一种研究药物（瑞德西韦）被推荐用于重症老年患者。如果一线药物治疗无效，可能会考虑使用其他不同研究报告的潜在药物。目前，尚无大型随机临床试验（RCT）的完整数据可提供有关使用、剂量或持续时间的临床指导，以验证所有试验药物在预防或治疗 COVID-19 方面的有效作用、安全性概况和不良反应。到目前为止，仍然不清楚哪种药物能够成功对抗这种疾病。因此，为了 COVID-19 患者的更好安全，需要进一步的临床试验和大型随机对照研究来验证所有潜在药物的有效作用、安全性概况和不良反应。这样的措施需要在全球范围内采取行动。
